your market intelligence analyst
Search Results
333 results
Your search is now limited to «Genetic Factors» expert search.
NASDAQ 02/27/2020 17:03
(RTTNews) - Biogen Inc. (BIIB) and Sangamo Therapeutics Inc. (SGMO), Thursday announced that they have reached a global collaboration deal to develop gene regulation therapies for Alzheimer's, Parkinson's, neuromuscular, and other neurological diseases.
More from NASDAQ:
STAT 02/27/2020 16:58
The drug maker Biogen announced late Thursday that it would license two preclinical drugs from Sangamo Therapeutics, both of which use a genome-editing technology called zinc fingers to regulate the expression of genes involved with neurological diseases like Alzheimer’s and Parkinson’s.
More from STAT:
Business Wire 02/27/2020 16:06
CAMBRIDGE, Mass. & BRISBANE, Calif.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets.
More from Business Wire:
Evidence from animal models has found that changes to regulation of the PSEN1 gene is associated with Alzheimer's-like pathology, but only a handful of studies have investigated DNA modification of the gene in humans.
More from Medical Xpress - Alzheimer's disease news, dementia news:
Becker's Hospital Review 02/27/2020 12:29
Health2047, the American Medical Association's innovation enterprise, announced on Feb. 27 its fourth spinout company: Medcurio, which develops software to improve healthcare organizations' data access and usage.
More from Becker's Hospital Review:
Alzforum News 02/26/2020 16:37
At the HAI 2020 conference, the tracers PI-2620 and APN-1607 appeared to bind frontotemporal dementia tau. MK-6240 looked highly sensitive. And JNJ-067 and SNFT-1 are two new kids in town.
More from Alzforum News: 02/26/2020 13:07
A recent study published in Nature has reported two conserved epigenetic regulators as novel anti-aging targets.
More from
Rapidly Progressing Neurocognitive Disorder in a Male with FXTAS and Alzheimer's Disease Elber Yuksel Aydin,1,2 Andrea Schneider,1,3 Dragana Protic,1,4 Jun Yi Wang,1,5 Veronica Martínez-Cerdeño,1,6 Flora Tassone,1,7 Hiu-Tung Tang,7 Susan Perlman,8 Randi J Hagerman1,3 1Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Sacramento, CA, USA; 2Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey; 3Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA, USA; 4Department of Pharmacology, Clinical Pharmacology and Toxicology, School of Medicine, University of Belgrade, Belgrade, Serbia; 5Center for Mind and Brain, University of California Davis.
More from International Journal of COPD:
GlobeNewswire 02/24/2020 08:30
The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease.
More from GlobeNewswire:
Fight Aging! 02/23/2020 09:55
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out more: Contents Request for Startups in the Rejuvenation Biotechnology Space, 2020 Edition Activating
More from Fight Aging!:
FeedNavigator (EU) 02/21/2020 14:11
Int J Mol Sci. 2020 Feb 14;21(4). pii: E1289. doi: 10.3390/ijms21041289.
More from FeedNavigator (EU):

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications